The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from PR Newswire

Valeant Pharmaceuticals Announces Continuance

Friday, August 09, 2013

Valeant Pharmaceuticals Announces Continuance

18:40 EDT Friday, August 09, 2013

LAVAL, Quebec, Aug. 9, 2013 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced that, effective August 9, 2013, it has continued from the federal jurisdiction of Canada to the Province of British Columbia (the "Continuance") pursuant to a resolution passed by shareholders of the Company at the annual meeting held May 21, 2013.  The Continuance results in the Company becoming subject to all of the provisions of the British Columbia Business Corporations Act.

About Valeant Pharmaceuticals International, Inc. Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, eye health, neurology and branded generics.  More information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com.

(Logo: http://photos.prnewswire.com/prnh/20101025/LA87217LOGO)

Contact Information:

Laurie W. Little 949-461-6002 laurie.little@valeant.com

SOURCE Valeant Pharmaceuticals International, Inc.

Products
  • Globe Unlimited

    Digital all access pass across devices. subscribe

  • The Globe and Mail Newspaper

    Newspaper delivered to your doorstep. subscribe

  • Globe2Go

    The digital replica of our newspaper. subscribe

  • Globe eBooks

    A collection of articles by the Globe. subscribe

See all Globe Products

Advertise with us

GlobeLink.ca

Your number one partner for reaching Canada's Influential Achievers. learn more

The Globe at your Workplace
Our Company
Customer Service
Globe Recognition
Mobile Apps
NEWS APP
INVESTING APP
Other Sections